Share on StockTwits

Covance (NYSE:CVD) has earned a consensus rating of “Hold” from the fifteen brokerages that are presently covering the stock, Analyst RN reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $93.04.

Shares of Covance (NYSE:CVD) opened at 97.52 on Tuesday. Covance has a 52 week low of $71.84 and a 52 week high of $106.50. The stock’s 50-day moving average is $101.7 and its 200-day moving average is $93.53. The company has a market cap of $5.523 billion and a price-to-earnings ratio of 30.96.

Covance (NYSE:CVD) last released its quarterly earnings data on Tuesday, February 4th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.84 by $0.03. The company had revenue of $623.00 million for the quarter, compared to the consensus estimate of $613.80 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 10.8% on a year-over-year basis. On average, analysts predict that Covance will post $3.85 earnings per share for the current fiscal year.

CVD has been the subject of a number of recent research reports. Analysts at Jefferies Group raised their price target on shares of Covance to $117.00 in a research note on Thursday, April 10th. They now have a “buy” rating on the stock. Separately, analysts at KeyCorp initiated coverage on shares of Covance in a research note on Wednesday, March 19th. They set a “buy” rating and a $120.00 price target on the stock. Finally, analysts at Barclays raised their price target on shares of Covance from $67.00 to $73.00 in a research note on Friday, March 7th. They now have an “underweight” rating on the stock.

Covance Inc is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.